Results 181 to 190 of about 53,097 (209)

A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

Annals of Oncology, 2010
Patrick Schöffski, Jean-Yves Blay, N Hollaender   +2 more
exaly  

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

Blood, 2009
Van Eygen Koen, Tara A Albrecht, Pierre Zachee   +2 more
exaly  

Imatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases

Journal of Controlled Release, 2012
Robbert Jan, W E Hennink
exaly  

Imatinib

Reactions Weekly, 2018
  +5 more sources

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Blood, 2007
Timothy Hughes, Hagop Kantarjian, Tadeusz Robak   +2 more
exaly  

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG

Leukemia, 2005
Stephanie Laufs, J Topaly, Melo J V
exaly  

Imatinib

Reactions Weekly, 2014
openaire   +1 more source

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

Lancet, The, 2004
Jean-Yves Blay, , Ian Judson
exaly  

Resistance to imatinib (Glivec): update on clinical mechanisms

Drug Resistance Updates, 2003
Ellen Weisberg, James Griffin
exaly  

Imatinib

Reactions Weekly, 2016
openaire   +2 more sources